Iovance Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IOVA | 0A3M.IL | IMCR | IDYA | INCY | 688382.SS | |
|---|---|---|---|---|---|---|
| Market cap | 3.94B | 25.17B | 1.51B | 3.12B | 25.04B | 8.38B |
| P/E (TTM) | — | 5.1 | — | — | 62.7 | — |
| Forward P/E | -44.4 | 5.1 | -37.7 | -7.9 | 14.2 | -43.8 |
| Price/book | 5.4 | 1.1 | 3.6 | 2.9 | 4.4 | 6.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +387.85% | −16.75% | −2.50% | +5.63% | +11.25% | −48.70% |
| Today | −1.47% | +2.81% | −2.66% | +3.29% | +4.47% | +4.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IOVA news ›Why Did IOVA Stock Jump Over 10% After-Hours Today?
Shares of Iovance Biotherapeutics (IOVA) jumped 12% in extended trading on Wednesday as an upcoming lung-cancer data presentation fueled optimism about its cell therapy’s potential beyond melanoma. IOVA stock rose nearly 2% Wednesday,…
More from 1 other outlet
Iovance Biotherapeutics to Host Webcast on Positive Phase 2 IOV-LUN-202 Results in Nonsquamous mNSCLC
Iovance Biotherapeutics will host a webcast on October 29, 2026, to discuss positive TIL therapy results and future opportunities. The Iovance conference call is scheduled for Thursday, October 29, 2026, at 8:30 a.m. ET. Lifileucel is a…
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
Updated phase 2 IOV-LUN-202 data show Iovance’s TIL cell therapy lifileucel produced a 24.6% response rate in previously treated non-squamous metastatic NSCLC, rising to 52.0% in KRAS and HER2 wild-type patients, as the company launches a…
Lifileucel Shows Durable Responses in Advanced Soft Tissue Sarcoma
Targeted Onc connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies. Patients with advanced soft tissue sarcomas have limited treatment options, particularly…
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Barclays analyst Etzer Darout maintained a Buy rating on Iovance Biotherapeutics today and set a price target of $18.00. According to TipRanks, Darout is a 5-star analyst with an average return of 27.2% and a 55.01% success rate. Darout…
Iovance Biotherapeutics Shows Market Leadership With Jump To 92 RS Rating
Iovance Biotherapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We…
Is 50% Crash Risk For Iovance Stock Real?
Shares of Iovance Biotherapeutics (IOVA) fell 35.4% on October 29, 2026, though the stock remains up 336.5% over the past year. Losing half its value is familiar territory for this stock. Across 5 of the 12 market shocks it has traded…
Iovance Biotherapeutics Stock Plunges 36% After Updated Lung Cancer Trial Data
Iovance Biotherapeutics, Inc. (IOVA) is down 35.76 percent, losing $5.30 to $9.52 on the Thursday. The decline follows updated results from Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial of lifileucel in previously treated non-squamous…
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer October 29, 2026 8:30 AM EDT Sara Pellegrino - Senior Vice President of Investor Relations & Corporate…
Iovance Stock Faces A 'Not Trivial' Problem That Will Slam 2022 Sales
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- investors.com3
- stocktwits.com3
- markets.businessinsider.com2
- rttnews.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 33 articles, not a forecast.